Cath Lab Digest - November 2007 - (Page 45)

NOVEMBER 2007 CLINICAL AND INDUSTRY NEWS 45 Tryton Medical’s Side-Branch Stent Demonstrates Unparalleled 6-Month Angiographic Restenosis Reductions Professor Patrick Serruys, MD, PhD, Presents Cardialaysis Core Laboratory Review of Tryton 1(First-in-Man Study) (n=30): No Side-Branch Restenosis, Late Loss of 0.27± 0.42 mm T ryton Medical, Inc. achieved a major medical milestone in stent technology with unprecedented six-month clinical and angiographic results from the Tryton 1 (First-In-Man Study). Dr. Ralf Müller (Helios Heart Center, Siegburg, Germany) and Professor Patrick W.J.C. Serruys (Erasmus Medical Center, Rotterdam, the Netherlands) presented the clinical and angiographic results at the European Bifurcation Club Meeting in Valencia, Spain. The Tryton SideBranch Stent™ was used in conjunction with a standard drug-eluting stent to treat 30 patients with coronary blockages involving large sidebranches. After 6 months, none of the patients suffered from sidebranch restenosis. Core laboratory quantitative analysis reported a late loss of 0.27 ± 0.42 mm in the side branch and 0.12 ± 0.47 mm in the main vessel. “The core angiographic data demonstrates that the hybrid approach, a bare metal Tryton SideBranch Stent used in conjunction with a standard drug-eluting stent, provides the same type of restenosis reduction we have seen when drugeluting stents are used to treat standard lesions,” said Professor Serruys, Erasmus Medical Center, the Netherlands. “The ability to treat bifurcation lesions have been a problem confronting us since the first days of angioplasty,” said Dr. Ralf Müller, Helios-Heart Center, Germany. “Tryton seamlessly integrates with other aspects of the angioplasty/stent procedure, allowing interventional cardiologists to treat this challenging patient subset with a high level of predictability and ease. The data shows that Tryton’s approach is not only safe, but it reduces restenosis to acceptable levels. I can now treat with confidence, this problem which I confront in nearly 20% of my cases,” Müller added. Every year, over half a million bifurcation coronary lesions are suboptimally treated as no commercially available optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent — leaving the side branch vulnerable to thrombosis and restenosis. “This technology has the capacity to redefine the treatment of bifurcation lesions and resolve a frequent dilemma of the interventional cardiologist,” said Dr. Serruys. ■ Bracco Diagnostics Inc. and HealthTrust Purchasing Group Sign a Three-Year Agreement for Contrast Media Toshiba America Medical Systems Vehicle Fleet Going Green Hybrid Vehicles Further Enhance Commitment to Reducing Carbon Footprint B racco Diagnostics Inc., the U.S.based subsidiary of Bracco Imaging SpA which is part of Bracco Group and HealthTrust Purchasing Group, a healthcare group purchasing organization in the United States, announced a three-year agreement to make Bracco Imaging SpA’s Magnetic Resonance Imaging (MRI) contrast media products available to HealthTrust members through 2010. This agreement includes MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL and ProHance ® (gadoteridol) injection 279.3 mg/mL. The agreement is effective September 1, 2007 and extends through August 31, 2010. HealthTrust members with questions regarding the new agreement are encouraged to contact their Bracco Imaging sales representative directly. For full Prescribing Information on both MultiHance and ProHance, please go to http://www.bracco.com/usa/enUS/Imaging/MRI/. ■ T oshiba America Medical Systems, Inc., offering diagnostic and medical imaging systems, announced its commitment to replacing the company’s entire fleet of sedans for its sales and service teams with hybrid cars over the next three years. As part of Toshiba Corporation’s global environmental initiative, Toshiba chose the Toyota Camry Hybrid to replace one-third of the current gas-only fleet each year. The first set of hybrid cars is scheduled to arrive in mid-to-late November 2007 and will be used by service and sales managers and account executives. With the addition of the Toyota Camry Hybrids, Toshiba expects to reduce fleet CO2 emissions by 25,000 pounds and save approximately $3 thousand to $4 thousand in fuel savings over the lifecycle of each vehicle. “The hybrids will take us closer to our goal of reducing emissions in logistics from company cars and freight by one percent each year,” said Paul Biggins, director of Regulatory Affairs and head of the TAMS’ Environmental Affairs Committee. Toshiba Corporation has set a global goal of reducing its energy-originated CO2 emissions by 25 percent by 2010 as well as non-CO2 greenhouse gas emissions by 35 percent by 2010. For more information, visit www.medical. toshiba.com. ■ Five-Gene Genetic Risk Score™ Identified, Predicts Risk of Coronary Heart Disease Findings May Complement Current Clinical Practices for Assessing Risk of CHD C elera, an Applera Corporation business, announced the publication of results from the Atherosclerosis Risk in Communities (ARIC) study and two independent case-control studies, describing the development of a Genetic Risk Score™ (GRS) based on five gene variants that predicts risk for coronary heart disease (CHD). These variant genes are KIF6, MYH15, PALLD, SNX19, and VAMP8. The GRS of each ARIC participant depended on how many of these risk variants an individual possessed. Continued on next page http://www.medical.toshiba.com http://www.medical.toshiba.com http://www.bracco.com/usa/enUS/Imaging/MRI/enUS/Imaging/MRI/ http://www.bracco.com/usa/enUS/Imaging/MRI/enUS/Imaging/MRI/

Table of Contents Feed for the Digital Edition of Cath Lab Digest - November 2007

Henry Ford Heart and Vascular Institute Treating Patients with Complex Vascular Disease with a Multi-Disciplinary Approach Improving Patient Compliance with Antiplatelet Medications Clinical Editor’s Corner Cath Lab Nurse/Tech Vascular Access and Closure Using the StarClose® Device The Clinical and Economic Impact of Measuring Fractional Flow Reserve FFR and Choosing an Optimal Revascularization Strategy Finally! The New Registered Cardiac Electrophysiology Specialist (RCES) Credential Use of a Mobile Lab to ‘Test the Waters’ at a Rural Hospital Remembering a Cardiac Cath Lab History ACVP• Membership Page What Do You Think? The Ten-Minute Interview with… Ernie Livingston, RN, BSN SICP* Chapter Updates Who’s in Charge? Working to Eliminate Bottlenecks: Florida Hospital’s Cardiac Cath Lab Achieves Greater Efficiency and Higher Satisfaction Preserving Left Ventricular Function during Percutaneous Coronary Intervention Ask the Clinical Instructor: A Q&A Column for Those New to the Cath Lab Making the Most of Your First Impression: Interviewing Tips and Techniques CEU Education Center Clinical & Industry News Meetings Calendar

Cath Lab Digest - November 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.